VisiPlate
Phase 1- Indications
- Open-angle glaucoma
Company intelligence / Profile preview
aVISI Pharma
Redwood City, California, United Statesavisitech.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The VisiPlate device demonstrated positive six-month interim results in the VITA clinical trial for open-angle glaucoma. The study showed a 40.4% reduction in mean intraocular pressure and reduced medication burden with a favorable safety profile—no significant vision loss or need for additional procedures[2][6].
- Therapeutic areas
- Ophthalmology
- Modalities
- DeviceNanotechnology-enabled implant
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical partnerships disclosed; collaborations with academic institutions such as University of Pennsylvania
Beyond the preview
Go deeper on aVISI Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aVISI Pharma.